Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands

Biochemical Journal

Volumn 372, Issue 3, 2003, Pages 747-755

  Pedersen, Katrine E ^a   Einholm, Anja P ^a   Christensen, Anni ^a   Schack, Lotte ^a   Wind, Troels ^a   Kenney, John M ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Cancer; Polymerization; Serpin; Thrombosis; Urokinase

Indexed keywords

ELECTROPHORESIS; MONOMERS; PATHOLOGY; POLYMERIZATION; POLYMERS;

ORGANOCHEMICAL LIGANDS;

ENZYME INHIBITION;

HEPARIN COFACTOR II; LIGAND; MUTANT PROTEIN; ORGANIC COMPOUND; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMER; PROTEINASE; SERINE PROTEINASE INHIBITOR; UROKINASE;

ARTICLE; BETA SHEET; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; MUTATION; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; TEMPERATURE DEPENDENCE;

AMINO ACID SEQUENCE; BINDING SITES; BIOPOLYMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEAT; HEPARIN COFACTOR II; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PAPAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SERPINS; SPECTROMETRY, FLUORESCENCE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0038266897     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20021868     Document Type: Article

References (51)

1. Carrell, R. W. and Owen, M. C. (1985) Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature (London) 317, 730-732
2. Irving, J. A., Pike, R. N., Lesk, A. M. and Whisstock, J. C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845-1864
3. Huber, R. and Carrell, R. W. (1989) Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry 28, 8951-8966
4. Gils, A. and Declerck, P. J. (1998) Structure-function relationships in serpins: current concepts and controversies. Thromb. Haemostasis 80, 531-541
5. Ye, S. and Goldsmith, E. J. (2001) Serpins and other covalent protease inhibitors. Curr. Opin. Struct. Biol. 11, 740-745
6. Wind, T., Hansen, M., Jensen, J. K. and Andreasen, P. A. (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol. Chem. 383, 21-36
7. Ye, S., Cech, A. L., Belmares, R., Bergstrom, R. C., Tong, Y., Corey, D. R., Kanost, M. R. and Goldsmith, E. J. (2001) The structure of a Michaelis serpin-protease complex. Nat. Struct. Biol. 8, 979-983
8. Lawrence, D. A., Ginsburg, D., Day, D. E., Berkenpas, M. B., Verhamme, I. M., Kvassman, J. O. and Shore, J. D. (1995) Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol. Chem. 270, 25309-25312
9. Shore, J. D., Day, D. E., Francis-Chmura, A. M., Verhamme, I., Kvassman, J., Lawrence, D. A. and Ginsburg, D. (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270, 5395-5398
10. Wilczynska, M., Fa, M., Ohlsson, P. I. and Ny, T. (1995) The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J. Biol. Chem. 270, 29652-29655
11. Egelund, R., Rodenburg, K. W., Andreasen, P. A., Rasmussen, M. S., Guldberg, R. E. and Petersen, T. E. (1998) An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 37, 6375-6379
12. Egelund, R., Petersen, T. E. and Andreasen, P. A. (2001) A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism. Eur. J. Biochem. 268, 673-685
13. Huntington, J. A., Read, R. J. and Carrell, R. W. (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature (London) 407, 923-926
14. Lawrence, D. A., Olson, S. T., Muhammad, S., Day, D. E., Kvassman, J. O., Ginsburg, D. and Shore, J. D. (2000) Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into β-sheet A. J. Biol. Chem. 275, 5839-5844
15. Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D. and Goldsmith, E. J. (1992) Structural basis of latency in plasminogen activator inhibitor-1. Nature (London) 355, 270-273
16. Carrell, R. W., Stein, P. E., Fermi, G. and Wardell, M. R. (1994) Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2, 257-270
17. Jin, L., Abrahams, J. P., Skinner, R., Petitou, M., Pike, R. N. and Carrell, R. W. (1997) The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U.S.A. 94, 14683-14688
18. Schreuder, H. A., de Boer, B., Dijkema, R., Mulders, J., Theunissen, H. J., Grootenhuis, P. D. and Hol, W. G. (1994) The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat. Struct. Biol. 1, 48-54
19. Sharp, A. M., Stein, P. E., Pannu, N. S., Carrell, R. W., Berkenpas, M. B., Ginsburg, D., Lawrence, D. A. and Read, R. J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure Fold. Des. 7, 111-118
20. Nar, H., Bauer, M., Stassen, J. M., Lang, D., Gils, A. and Declerck, P. J. (2000) Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 297, 683-695
21. Stout, T. J., Graham, H., Buckley, D. I. and Matthews, D. J. (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39, 8460-8469
22. Lomas, D. A. and Carrell, R. W. (2002) Human genetics and disease: Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3, 759-768
23. Huntington, J. A., Pannu, N. S., Hazes, B., Read, R. J., Lomas, D. A. and Carrell, R. W. (1999) A 2.6 Å structure of a serpin polymer and implications for conformational disease. J. Mol. Biol. 293, 449-455
24. Dunstone, M. A., Dai, W., Whisstock, J. C., Rossjohn, J., Pike, R. N., Feil, S. C., Le Bonniec, B. F., Parker, M. W. and Bottomley, S. P. (2000) Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 9, 417-420
25. Elliott, P. R., Pei, X. Y., Dafforn, T. R. and Lomas, D. A. (2000) Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9, 1274-1281
26. Björquist, P., Ehnebom, J., Inghard, T., Hansson, L., Lindberg, M., Linschoten, M., Strömqvist, M. and Deinum, J. (1998) Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37, 1227-1234
27. Egelund, R., Einholm, A. P., Pedersen, K. E., Nielsen, R. W., Christensen, A., Deinum, J. and Andreasen, P. A. (2001) A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization. J. Biol. Chem. 276, 13077-13086
28. Munch, M., Heegaard, C. W. and Andreasen, P. A. (1993) Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta 1202, 29-37
29. Berkenpas, M. B., Lawrence, D. A. and Ginsburg, D. (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977
30. Hansen, M., Busse, M. N. and Andreasen, P. A. (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur. J. Biochem. 268, 6274-6283
31. von Heijne, G. (1984) How signal sequences maintain cleavage specificity. J. Mol. Biol. 173, 243-251
32. Jensen, J. K., Wind, T. and Andreasen, P. A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett. 521, 91-94
33. Wind, T., Jensen, M. A. and Andreasen, P. A. (2001) Epitope mapping for tour monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur. J. Biochem. 268, 1095-1106
34. Schägger, H. and von Jagow, G. (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 199, 223-231
35. Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723
36. Munch, M., Heegaard, C., Jensen, P. H. and Andreasen, P. A. (1991) Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett. 295, 102-106
37. Lomas, D. A., Evans, D. L., Stone, S. R., Chang, W. S. and Carrell, R. W. (1993) Effect of the Z mutation on the physical and inhibitory properties of α1-antitrypsin. Biochemistry 32, 500-508
38. Egelund, R., Schousboe, S. L., Sottrup-Jensen, L., Rodenburg, K. W. and Andreasen, P. A. (1997) Type-1 plasminogen-activator inhibitor - conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur. J. Biochem. 248, 775-785
39. Kjøller, L., Martensen, P. M., Sottrup-Jensen, L., Justesen, J., Rodenburg, K. W. and Andreasen, P. A. (1996) Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Eur. J. Biochem. 241, 38-46
40. Xue, Y., Björquist, P., Inghardt, T., Linschoten, M., Musil, D., Sjölin, L. and Deinum, J. (1998) Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6, 627-636
41. Dumery, L., Bourdel, F., Soussan, Y., Fialkowsky, A., Viale, S., Nicolas, P. and Reboud-Ravaux, M. (2001) β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. Pathol. Biol. (Paris) 49, 72-85
42. Lücking, C. B. and Brice, A. (2000) α-Synuclein and Parkinson's disease. Cell. Mol. Life Sci. 57, 1894-1908
43. Mast, A. E., Enghild, J. J. and Salvesen, G. (1992) Conformation of the reactive site Loop of α1-proteinase inhibitor probed by limited proteolysis. Biochemistry 31, 2720-2728
44. Preissner, K. T. (1993) Self-association of antithrombin III relates to multimer formation of thrombin-antithrombin III complexes. Thromb. Haemostasis 69, 422-429
45. Mikus, P., Urano, T., Liljeström, P. and Ny, T. (1993) Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur. J. Biochem. 218, 1071-1082
46. Patston, P. A., Hauert, J., Michaud, M. and Schapira, M. (1995) Formation and properties of C1-inhibitor polymers. FEBS Lett. 368, 401-404
47. Baglin, T. P., Carrell, R. W., Church, F. C., Esmon, C. T. and Huntington, J. A. (2002) Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. U.S.A. 99, 11079-11084
48. Huber, K., Christ, G., Wojta, J. and Gulba, D. (2001) Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report (2001) Thromb. Res. 103, S7-S19
49. Andreasen, P. A., Pyke, C., Riccio, A., Kristensen, P., Nielsen, L. S., Lund, L. R., Blasi, F. and Danø, K. (1987) Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells. Mol. Cell. Biol. 7, 3021-3025
50. Booth, N. A., Simpson, A. J., Croll, A., Bennett, B. and MacGregor, I. R. (1988) Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br. J. Haematol. 70, 327-333
51. Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F. and Danø, K. (1986) Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 209, 213-218